POS0976 IMPACT OF PATIENT AND DISEASE CHARACTERISTICS ON GLOBAL FUNCTIONING AND HEALTH IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A BAYESIAN NETWORK ANALYSIS OF DATA FROM AN EARLY axSpA COHORT
Authors: I. Redeker, R. B. M. Landewé, D. Van der Heijde, S. Ramiro, A. Boonen, M. Dougados, J. Braun, U. Kiltz
Journal: Annals of the Rheumatic Diseases (2022)

Background Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic measure for physical- or mental health (SF36), a hierarchical relationship between disease activity, spinal damage, spinal mobility, physical function and overall health has been demonstrated in pts. with radiographic axSpA (r-axSpA) 1 . Disease-specific global functioning and health can be assessed in pts. with axSpA using the ASAS Health Index (ASAS HI), which encompasses physical function, as well as aspects of emotional and social functioning and aspects of activity and participation. Objectives To build a structural model that visualizes interrelationships of different patient- and disease characteristics with global functioning and health in pts. with early axSpA. Methods Data of pts. with axSpA from the DESIR cohort was analyzed, which included information on socio-demographics (age, BMI), disease activity (ASDAS), physical function (BASFI), spinal mobility (BASMI), structural damage (mSASSS), disease-specific global functioning (ASAS HI), and comorbidity count. Information on patient- and disease characteristics was retrieved from the visit performed 72 months after inclusion, which was the first time point of ASAS HI collection. A Bayesian network (BN) was used to obtain insight of the underlying structural model. BNs are probabilistic graphical models consisting of “nodes” (representing specific variables) joined by “edges” (lines representing directions of effects). They are capable of capturing complex relationships between variables and allow the incorporation of existing (prior) knowledge from previous studies. Results The DESIR cohort contained data from 582 pts. at month 72, of whom 398 had data for ASAS HI. Descriptive information of these pts. is shown in Table 1. The mean ASAS HI was 5.7 (range: 0 - 16). Applying existing cut-offs for ASAS HI, 51% had ‘good’ global functioning (ASAS HI ≥5), 40% had ‘moderate’ global functioning (5&lt; ASAS HI &lt;12) and 9% had ‘bad’ global functioning (ASAS HI ≥12). The structural model that was constructed from combining data and prior expert knowledge is visualized in Figure 1. It suggests that ASDAS and BASFI have a direct impact on ASAS HI and that ASDAS has an indirect impact via BASFI. The model also suggests that ASDAS has an impact on the number of co-morbidities via BMI and that BASFI determines BASMI, which is in turn also influenced by age and mSASSS. In addition, it suggests a direct effect of age, BMI and ASAS HI on the comorbidity count. The model denies a relationship between BASMI or mSASSS and ASAS HI. Table 1. Patient and disease characteristics at month 72 N = 398 Gender (male), N (%) 181 (45%) Age (years) 40.7 (8.7) Symptom duration (years) 7.5 (0.9) BMI (kg/m 2 ) 25.0 (4.6) ASDAS 2.0 (1.0) BASFI (0–10) 2.3 (2.1) BASMI (0–10) 2.5 (1.0) mSASSS (0-72) 1.0 (3.6) ASAS HI (0-17) 5.7 (3.9) good global functioning: ASAS HI ≤5, N (%) 201 (51%) moderate global functioning: 5&lt; ASAS HI &lt;12, N (%) 160 (40%) bad global functioning: ASAS HI ≥12, N (%) 37 (9%) Comorbidity count 1.4 (0.7) Figure 1. Structural model on interrelationships of different patient- and disease characteristics with global functioning and health (ASAS HI) in patients with early axSpA Conclusion The BN-analysis approach, that combines prior knowledge and measured data, serves to better understand the construct of global functioning and health in pts. with early axSpA. Our model shows that global functioning (ASAS-HI) is determined both by patient-reported physical function (BASFI) and by disease activity (ASDAS), which confirms the hierarchical model once proposed by Machado et al. The observed directional relationship between ASAS HI and comorbidity count is counterintuitive and requires further investigation. References [1]Machado P, ARD 2011. Disclosure of Interests Imke Redeker: None declared, Robert B.M. Landewé Speakers bureau: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Consultant of: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Désirée van der Heijde Speakers bureau: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Sofia Ramiro Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi, Grant/research support from: AbbVie, Galapagos, Novartis, Pfizer, UCB, Annelies Boonen Speakers bureau: Abbvie / Galapagos, Consultant of: Galapagos, Grant/research support from: Abbvie, Maxime Dougados: None declared, Juergen Braun Speakers bureau: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Consultant of: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Grant/research support from: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Uta Kiltz Speakers bureau: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Grant/research support from: AbbVie, Biogen, Fresenius, Amgen, Hexal, Novartis, Pfizer